ArticleJournal of autoimmunity2018
Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.
Article in Journal of autoimmunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- The Antigen Presenting Potential of CD21Frontiers in immunology · 2020Trial
- Immunophenotypic insights into diabetes heterogeneity: The role of CD25-expressing T cells in Ghanaian type 1 diabetes cohorts.Journal of translational autoimmunity · 2026Article
- CCL17-neutralizing and esterase-responsive core-shell microgels for endogenous Tregs recruitment and functional enhancement in myocardial infarction.Bioactive materials · 2026Article
- T Regulatory Mechanisms in Airway and Interstitial Lung Disease.Seminars in respiratory and critical care medicine · 2025Review
- Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.Frontiers in immunology · 2023Review
- Post-COVID-19 Immune-Mediated Neurological Complications in Children: An Ambispective Study.Pediatric neurology · 2022Article
- Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- Interleukin-2 expands neuroprotective regulatory T cells in Parkinson's disease.NeuroImmune pharmacology and therapeutics · 2022Article
- Identification of an immune-related gene prognostic index for predicting prognosis, immunotherapeutic efficacy, and candidate drugs in amyotrophic lateral sclerosis.Frontiers in cellular neuroscience · 2022Article
- Auto-antigen and Immunomodulatory Agent-Based Approaches for Antigen-Specific Tolerance in NOD Mice.Current diabetes reports · 2021Review
- Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3Cellular immunology · 2020Review
- Post-infectious neurological disorders.Therapeutic advances in neurological disorders · 2020Review
- Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy.Frontiers in immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cell (DC)-mediated T cell tolerance deficiencies contribute to the pathogenesis of autoimmune diseases such as type 1 diabetes. Delivering self-antigen to dendritic-cell inhibitory receptor-2 (DCIR2)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.